Gleb Fomin

Gleb Fomin

Auto-generated profile, based on publicly available information

Gleb Fomin

International Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KTKairat Tabynov
Kairat Tabynov
NTNurkeldi Turebekov
Nurkeldi Turebekov
MBMeruert Babayeva
Meruert Babayeva
GFGleb Fomin
Gleb Fomin
TYToktassyn Yerubayev
Toktassyn Yerubayev
KTKaissar Tabynov
Kaissar Tabynov
Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.